Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.38.

A number of analysts recently weighed in on OCUL shares. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC assumed coverage on Ocular Therapeutix in a report on Tuesday, March 11th. They issued a "buy" rating and a $15.00 price target on the stock. Finally, Royal Bank of Canada started coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock traded down $0.64 on Tuesday, reaching $6.36. The company's stock had a trading volume of 2,891,880 shares, compared to its average volume of 1,560,783. The business's fifty day moving average price is $7.42 and its 200 day moving average price is $8.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -4.82 and a beta of 1.49. Ocular Therapeutix has a twelve month low of $4.06 and a twelve month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Equities analysts expect that Ocular Therapeutix will post -0.98 earnings per share for the current fiscal year.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Donald Notman sold 6,301 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the sale, the insider now owns 204,563 shares of the company's stock, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,895 shares of company stock worth $283,772. 3.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth about $28,000. Atlas Capital Advisors Inc. bought a new position in Ocular Therapeutix in the fourth quarter valued at approximately $43,000. AlphaQuest LLC acquired a new position in shares of Ocular Therapeutix in the fourth quarter valued at approximately $53,000. Tower Research Capital LLC TRC increased its position in shares of Ocular Therapeutix by 2,045.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after acquiring an additional 8,446 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth $90,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.